Stockscreener 앱 받기
3.74
3.11%
-0.12
시간 외 거래:
3.74
Whitehawk Therapeutics Inc 주식(WHWK)의 최신 뉴스
Insiders At Whitehawk Therapeutics Sold US$2.5m In Stock, Alluding To Potential Weakness - simplywall.st
WHWK News | WHITEHAWK THERAPEUTICS INC (NASDAQ:WHWK) - ChartMill
WHWK - Finviz
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to S&P Global BMI Index - marketscreener.com
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know - Eastern Progress
Whitehawk (WHWK) clarifies CSO RSU vesting terms - Stock Titan
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Update - MarketBeat
Whitehawk Therapeutics advances next-gen ADC ca... - pluang.com
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 - The Journal Gazette
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Whitehawk Therapeutics Adds Oncology Leader to Board - The Globe and Mail
Whitehawk Therapeutics appoints Vijay Iyengar to board By Investing.com - Investing.com South Africa
Oncology veteran Vijay Iyengar joins Whitehawk Therapeutics (WHWK) board - Stock Titan
Whitehawk Therapeutics appoints Vijay Iyengar to board - investing.com
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, To Board Of Directors - TradingView
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors - PR Newswire
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - Stocktwits
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) Stock Price, News & Analysis - Kalkine
BlackRock Inc. Makes New $8.81 Million Investment in Whitehawk Therapeutics, Inc. $WHWK - marketbeat.com
WHWK Q2 2026 Earnings: Narrower Loss Beats Estimates by 33.73%, Stock Slips 1.7%Margin Guidance - dars.gov.et
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
Montanova Capital LLC Has $19.69 Million Position in Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
WHWK Q2 2026 Earnings: 33.7% EPS Surprise Highlights Cost Discipline Despite Share SlipEarnings Season Preview - careplusvn.com
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now? - Yahoo Finance
WHWK | Whitehawk Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Whitehawk (WHWK) Shares: Finishes 2.31% Up at $4.87 on the Day; Next Test: the $4.63 to $5.11 Range Remains in FocusCall Resistance - vinanet.vn
Whitehawk (WHWK) Watch: Gains 2.94% to Reach $4.90 in the Latest Session; Range Check: $4.66 and $5.15 Define the Nearby Reference Levels at the CloseRetail Driven Moves - Vinanet
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
WHWK Q2 2026 Earnings: Narrower-than-Expected Loss Beats Estimates, Shares Rise 4.04%Net Profit Margin - vinanet.vn
WHWK Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 33.73% EPS Surprise, Shares Rise 4.04% - vinanet.vn
Whitehawk Therapeutics (WHWK) Jumps 4.5% to $4.66, Edges Toward Key ResistanceBackspread Trade - vinanet.vn
Whitehawk Therapeutics (WHWK) Drops 4.7% to $4.46, Approaches Key Support at $4.24Diagonal Spread Trade - vinanet.vn
Whitehawk Therapeutics (WHWK): OrbiMed entities disclose 3.93M-share, 7.3% ownership stake - Stock Titan
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform - Yahoo Finance
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Season Preview - careplusvn.com
Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Aadi Bioscience Inc (3350.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Whitehawk Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Whitehawk Therapeutics 2Q 2026: Revenue $0 Net loss $16.64M, EPS $(0.20) — 10-Q Summary - tradingview.com
Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 - TradingView
Whitehawk Therapeutics reports $16.6 million Q2 loss as trials advance - Quiver Quantitative
Whitehawk Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Whitehawk Therapeutics 2Q Loss/Shr 20c >WHWK - Moomoo
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire
Whitehawk Therapeutics (WHWK) Slips 1.7% as Shares Hover Between Support and ResistanceWave Extension - dars.gov.et
Akari Therapeutics Highlights WhiteHawk Collaboration and Dual-Payload ADC Strategy in CEO Corner Segment - Quiver Quantitative
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - Yahoo Finance
WHWK Q1 2026 Earnings: Narrower-than-Expected Loss Points to Cost DisciplineGuidance Update - vinanet.vn
Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
WHWK Q1 2026 Earnings: Smaller-than-Expected Loss Beats Estimates Amid Pre-Revenue StatusEarnings Sentiment Score - careplusvn.com
Whitehawk Therapeutics Inc (WHWK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WHWK|WHWK|Price:3.940|Chg%:+0.090 - TradingKey
3.06%
2.55%
자본화:
|
볼륨(24시간):